Table 3 Case attributes by region (N = 332)
Zone | Variable | East Asia* | West Asiaa | Eastern Europeb | Western Europec | Americas and Oceaniad | df | χ2 | Sig. | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
N | % | N | % | N | % | N | % | N | % | Sig. | ||||
81 | 24.4 | 65 | 19.6 | 158 | 47.6 | 20 | 6.0 | 8 | 2.4 | |||||
Gender | 4 | 25.12 | ||||||||||||
Male | 77 | 95.1 | 62 | 95.4 | 123 | 77.8 | 20 | 100.0 | 8 | 100 | <.0005 | |||
Female | 3 | 4.9 | 3 | 4.6 | 35 | 22.2 | 0 | 0.0 | 0 | – | ||||
Year | 20 | 124.40 | ||||||||||||
2012 | 14 | 17.3 | 1 | 1.5 | 2 | 1.3 | 7 | 35.0 | 0 | 0.0 | <.0005 | |||
2013 | 1 | 1.2 | 24 | 36.9 | 22 | 13.9 | 5 | 25.0 | 0 | 0.0 | ||||
2014 | 15 | 18.5 | 16 | 24.6 | 16 | 10.1 | 3 | 15.0 | 1 | 12.5 | ||||
2015 | 16 | 19.8 | 12 | 18.5 | 16 | 10.1 | 0 | 0.0 | 1 | 12.5 | ||||
2016 | 20 | 24.7 | 4 | 6.2 | 65 | 41.2 | 0 | 0.0 | 2 | 25.0 | ||||
2017 | 15 | 18.5 | 8 | 12.3 | 37 | 23.4 | 5 | 25.0 | 4 | 50.0 | ||||
Place of Seizure | 12 | 163.64 | ||||||||||||
Land and Air ports of entry | 26 | 32.1 | 41 | 63.1 | 13 | 8.3 | 0 | 0.0 | 0 | 0.0 | <.0005 | |||
Mail and Packages processing centers | 51 | 63.0 | 6 | 9.2 | 144 | 91.2 | 17 | 85.0 | 8 | 100.0 | ||||
Private premises | 3 | 3.7 | 12 | 18.5 | 1 | 0.6 | 3 | 15.0 | 0 | 0.0 | ||||
Public or commercial properties | 1 | 1.2 | 6 | 9.2 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | ||||
Type of substance | ||||||||||||||
Adrenergic and sympathomimetic agents | 4 | 4.9 | 1 | 1.5 | 11 | 3.3 | 5 | 1.5 | 0 | 0.0 | ||||
Anabolic Steroids | 69 | 85.2 | 49 | 75.4 | 133 | 84.2 | 13 | 65.0 | 5 | 62.5 | ||||
Diuretics, Sodium and potassium supplements | 0 | 0.0 | 2 | 3.1 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 20 | 127.63 | ||
Hormones, Growth hormones, and hormone releasing agents | 7 | 8.6 | 7 | 10.8 | 5 | 3.2 | 1 | 5.0 | 0 | 0.0 | <.0005 | |||
Post-cycle and adverse effects treatment agents | 0 | 0.0 | 6 | 9.2 | 9 | 5.7 | 1 | 5.0 | 0 | 0.0 | ||||
Site enhancing oils | 1 | 1.2 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 3 | 37.5 | ||||